» Articles » PMID: 33177593

Concordance in Detecting Amyloid Positivity Between F-florbetaben and F-flutemetamol Amyloid PET Using Quantitative and Qualitative Assessments

Overview
Journal Sci Rep
Specialty Science
Date 2020 Nov 12
PMID 33177593
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

We aimed to quantitatively and qualitatively assess whether there is a discrepancy in detecting amyloid beta (Aβ) positivity between 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) positron emission tomography (PET). We obtained paired FBB and FMM PET images from 107 participants. Three experts visually quantified the Aβ deposition as positive or negative. Quantitative assessment was performed using global cortical standardized uptake value ratio (SUVR) with the whole cerebellum as the reference region. Inter-rater agreement was excellent for FBB and FMM. The concordance rates between FBB and FMM were 94.4% (101/107) for visual assessment and 98.1% (105/107) for SUVR cut-off categorization. Both FBB and FMM showed high agreement rates between visual assessment and SUVR positive or negative categorization (93.5% in FBB and 91.2% in FMM). When the two ligands were compared based on SUVR cut-off categorization as standard of truth, although not statistically significant, the false-positive rate was higher in FMM (9.1%) than in FBB (1.8%) (p = 0.13). Our findings suggested that both FBB and FMM had excellent agreement when used to quantitatively and qualitatively evaluate Aβ deposits, thus, combining amyloid PET data associated with the use of different ligands from multi-centers is feasible.

Citing Articles

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.

Leuzy A, Bollack A, Pellegrino D, Teunissen C, La Joie R, Rabinovici G Alzheimers Dement. 2025; 21(3):e14528.

PMID: 40042435 PMC: 11881640. DOI: 10.1002/alz.14528.


Clinical application of sparse canonical correlation analysis to detect genetic associations with cortical thickness in Alzheimer's disease.

Kim B, Seo S, Park Y, Kim J, Kim H, Jang H Front Neurosci. 2024; 18:1428900.

PMID: 39381682 PMC: 11458562. DOI: 10.3389/fnins.2024.1428900.


New objective simple evaluation methods of amyloid PET/CT using whole-brain histogram and Top20%-Map.

Okuyama C, Higashi T, Ishizu K, Oishi N, Kusano K, Ito M Ann Nucl Med. 2024; 38(9):763-773.

PMID: 38907835 PMC: 11339116. DOI: 10.1007/s12149-024-01956-y.


Improving diagnostic precision in amyloid brain PET imaging through data-driven motion correction.

Park H, Park S, Kim M, Paeng S, Min E, Hong I EJNMMI Phys. 2024; 11(1):49.

PMID: 38874674 PMC: 11178732. DOI: 10.1186/s40658-024-00653-z.


Validation of quantitative assessment of florbetaben PET scans as an adjunct to the visual assessment across 15 software methods.

Jovalekic A, Roe-Vellve N, Koglin N, Quintana M, Nelson A, Diemling M Eur J Nucl Med Mol Imaging. 2023; 50(11):3276-3289.

PMID: 37300571 PMC: 10542295. DOI: 10.1007/s00259-023-06279-0.


References
1.
Sabri O, Sabbagh M, Seibyl J, Barthel H, Akatsu H, Ouchi Y . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015; 11(8):964-74. DOI: 10.1016/j.jalz.2015.02.004. View

2.
Cho S, Choe Y, Kim H, Jang H, Kim Y, Kim S . A new Centiloid method for F-florbetaben and F-flutemetamol PET without conversion to PiB. Eur J Nucl Med Mol Imaging. 2019; 47(8):1938-1948. DOI: 10.1007/s00259-019-04596-x. View

3.
Park J, Seo S, Kim C, Kim S, Kim G, Kim S . Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiol Aging. 2013; 35(1):254-60. PMC: 5849054. DOI: 10.1016/j.neurobiolaging.2013.06.026. View

4.
Salloway S, Gamez J, Singh U, Sadowsky C, Villena T, Sabbagh M . Performance of [F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. Alzheimers Dement (Amst). 2017; 9:25-34. PMC: 5536824. DOI: 10.1016/j.dadm.2017.06.001. View

5.
Petersen R, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E . Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56(3):303-8. DOI: 10.1001/archneur.56.3.303. View